Drug Database
Back to search

Belgium· BE-AMP-SAM156922-00

Inhibace 5 mg

A cilazapril product containing cilazapril monohydrate, registered in Belgium by Cheplapharm Arzneimittel. The same ATC class is registered in 10 of our 19 countries.

ATC C09AA08

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedInhibace 5 mgATCC09AA08REGISTER NO.BE-AMP-SAM156922-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cilazapril monohydrateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cilazapril is registered in 10 of 19 countries.

Countries holding a registration under ATC C09AA08 (cilazapril), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search cilazapril products by name

Cilazapril · ATC C09AA08

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Germany
  • Italyprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cilazapril costs, country by country.

Normalised to the WHO defined daily dose (2.5 mg), the median price runs from $0.22 in Spain to $0.53 in Switzerland — a ×2.4 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cilazapril · price per daily dose (2.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.53
  • IT Italy$0.45
  • ES Spain$0.22
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Cilazapril Monohydrate
Manufacturer
Cheplapharm Arzneimittel
Country
Belgium (BE)
ATC code
C09AA08
ATC class
Cilazapril
Defined daily dose
2.5 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    0287961
    EUR 18.47
  • be_apb
    0739136

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

69 interactions on record for cilazapril.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cilazapril against other medicinesHow interaction checks work

Cilazapril · interactions on record

69 records

69 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Cilazapril in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cilazapril products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Austria · Inhibace
  • Czechia · Cazaprol, Inhibace
  • Germany · Dynorm
  • United Kingdom (Northern Ireland) · Cilazapril Activase Pharmaceuticals
  • Greece · Vascace
  • Hungary · Inhibace
  • Italy · Inibace, Initiss
  • Poland · Cilan, Inhibace
  • Portugal · Cilazapril Generis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec376faa-81c0-4648-97d0-337a00207345
GET /v1/drugs/ec376faa-81c0-4648-97d0-337a00207345?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Inhibace 5 mg",
  "name_fr": "Inhibace 5 mg",
  "name_nl": "Inhibace 5 mg",
  "amp_code": "SAM156922-00",
  "strengths": [
    "5.2200",
    "5.2200",
    "5.0000",
    "5.0000",
    "121.7800",
    "2.0000"
  ],
  "pack_count": 10,
  "substances": [
    "Cilazapril Monohydrate",
    "Cilazapril",
    "Lactose Monohydrate",
    "Sodium Stearyl Fumarate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Cilazapril",
  "authorisation_numbers": [
    "BE156922",
    "BE448595"
  ]
}
API referenceMCP serverPlans

See everything about cilazapril.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console